What FDA decisions have you missed recently?  Continue Reading..

Within the last 10 years, a number of nonprofit groups, including the Michael J. Fox Foundation and the Multiple Myeloma Research Foundation, have taken a similar approach to ensuring that their targeted patient populations are being well represented in pharma R&D.  Continue Reading..

What FDA decisions have you missed recently?  Continue Reading..

As the call for transparency grows louder in the pharma industry, the question arises: are drugmakers equipped with all they need to be transparent — especially when it comes to demonstrating their drugs’ economic value?  Continue Reading..

A report from the Bureau of Labor Statistics found that nationwide employment in “pharmaceutical and medicine manufacturing” sunk from 291,795 in 2003 to 277,113 in 2013, The Philadelphia Inquirer reported recently. But it’s not the same story for biotech R&D: employment hit 142,475 in 2013 — up from 135,424 in 2007.  Continue Reading..

What regulatory decisions have you missed recently?  Continue Reading..

If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.  Continue Reading..

There’s a new partnership under way in the quest for the long-sought-after cure for HIV. Last month, GSK teamed up with the University of North Carolina at Chapel Hill to form a research institute and a company dedicated to finding a cure for HIV and AIDS. GSK will shell out $4 million annually over the next five years to launch the research center on Chapel Hill’s campus.  Continue Reading..

What FDA decisions have you missed recently?  Continue Reading..

What FDA decisions have you missed recently?  Continue Reading..